Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer

被引:56
|
作者
Humphries, Brock A. [1 ]
Buschhaus, Johanna M. [1 ,2 ]
Chen, Yu-Chih [3 ,4 ,5 ]
Haley, Henry R. [1 ]
Qyli, Tonela [1 ]
Chiang, Benjamin [1 ]
Shen, Nathan [1 ]
Rajendran, Shrila [1 ]
Cutter, Alyssa [1 ]
Cheng, Yu-Heng [3 ]
Chen, Yu-Ting [6 ]
Cong, Jason [6 ]
Spinosa, Phillip C. [7 ]
Yoon, Euisik [2 ,3 ]
Luker, Kathryn E. [1 ]
Luker, Gary D. [1 ,2 ,8 ]
机构
[1] Univ Michigan, Dept Radiol, Ctr Mol Imaging, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Elect Engn & Comp Sci, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Forbes Inst Canc Discovery, Ann Arbor, MI 48109 USA
[6] UCLA, Comp Sci Dept, Boelter Hall, Los Angeles, CA USA
[7] Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA
[8] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA
关键词
MITOCHONDRIAL FISSION; CELLS; GROWTH; PHOSPHORYLATION; SENSITIVITY; GENERATION; PAXILLIN; PROTEIN; MATRIX; ERK;
D O I
10.1158/1541-7786.MCR-18-0836
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Migration and invasion of cancer cells constitute fundamental processes in tumor progression and metastasis. Migratory cancer cells commonly upregulate expression of plasminogen activator inhibitor 1 (PAI1), and PAI1 correlates with poor prognosis in breast cancer. However, mechanisms by which PAI1 promotes migration of cancer cells remain incompletely defined. Here we show that increased PAI1 drives rearrangement of the actin cytoskeleton, mitochondrial fragmentation, and glycolytic metabolism in triple-negative breast cancer (TNBC) cells. In two-dimensional environments, both stable expression of PAI1 and treatment with recombinant PAI1 increased migration, which could be blocked with the specific inhibitor tiplaxtinin. PAI1 also promoted invasion into the extracellular matrix from coculture spheroids with human mammary fibroblasts in fibrin gels. Elevated cellular PAI1 enhanced cytoskeletal features associated with migration, actin-rich migratory structures, and reduced actin stress fibers. In orthotopic tumor xenografts, we discovered that TNBC cells with elevated PAI1 show collagen fibers aligned perpendicular to the tumor margin, an established marker of invasive breast tumors. Further studies revealed that PAI1 activates ERK signaling, a central regulator of motility, and promotes mitochondrial fragmentation. Consistent with known effects of mitochondrial fragmentation on metabolism, fluorescence lifetime imaging microscopy of endogenous NADH showed that PAI1 promotes glycolysis in cell-based assays, orthotopic tumor xenografts, and lung metastases. Together, these data demonstrate for the first time that PAI1 regulates cancer cell metabolism and suggest targeting metabolism to block motility and tumor progression.
引用
收藏
页码:1142 / 1154
页数:13
相关论文
共 50 条
  • [1] The Role of the Plasminogen Activator Inhibitor 1 ( PAI1 ) in Ovarian Cancer: Mechanisms and Therapeutic Implications
    Mathews, Sneha Grace
    Krishna, R. B. Devi
    Lavanya, M.
    Nandini, K.
    Murali, Sanjana
    Agarwal, Preet
    Rani, Elizabeth
    Andrea Mary, F.
    GLOBAL MEDICAL GENETICS, 2024, 11 (04): : 358 - 365
  • [2] NEGATIVE PROGNOSTIC VALUE OF PLASMA PAI-1 (PLASMINOGEN ACTIVATOR INHIBITOR-1) LEVELS IN BREAST CANCER PATIENTS
    Ferroni, P.
    Palmirotta, R.
    Savonarola, A.
    Martini, F.
    Ciatti, F.
    Laudisi, A.
    Fossile, E.
    Del Monte, G.
    Roselli, M.
    Guadagni, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 54 - 54
  • [3] Hyperfibrinolysis as an undiagnosed cause of haemorrhage: Evaluation of 67 individuals with plasminogen activator inhibitor 1 (PAI1) deficiency
    Brito, C.
    Cruz, E.
    Falavigna, M.
    Damasio, I.
    Dias, F.
    Pereira, M.
    Matos, R.
    Moreira, L.
    Pinho, N.
    Seidi, N.
    Coutinho, M.
    Morais, S.
    HAEMOPHILIA, 2024, 30 : 147 - 148
  • [4] Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A
    Soliman, Mohamed
    Osman, Nahla
    Hefnawy, Somyya
    El Hawy, Mahmoud Ahmed
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2022, 39 (04) : 318 - 328
  • [5] UCHL1 promotes cancer stemness in triple-negative breast cancer
    Tian, Chuntao
    Liu, Ying
    Liu, Yixiong
    Hu, Peizhen
    Xie, Shenglong
    Guo, Yu
    Wang, Hui
    Zhang, Zhiyong
    Du, Liuyang
    Lei, Binhua
    Wang, Yingping
    Xue, Lingfei
    Zhang, Dong
    Su, Jing
    Zhang, Xiaotong
    Zhang, Ruiwen
    Chen, Jiaohong
    Zhang, Xiangqian
    Chen, Ligang
    Li, Mingyang
    Jia, Qingge
    Song, Junyang
    Liu, Jin
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 240
  • [6] Inhibition of plasminogen activator inhibitor-1 (PAI-1) promotes adipocyte differentiation
    Liang, XB
    Declerck, PJ
    Wasserman, DH
    Fogo, AB
    Ma, LY
    DIABETES, 2005, 54 : A444 - A444
  • [7] Assessment of Plasminogen Activator Inhibitor-1(PAI-1) Biomarker in Women with Breast Cancer Disease
    AL-Nafakh, Zahraa Mohammed
    AL-Dujaili, Arshad Noori G.
    Rudha, Ammar Rasoul Mohammed
    8TH INTERNATIONAL CONFERENCE ON APPLIED SCIENCE AND TECHNOLOGY (ICAST 2020), 2020, 2290
  • [8] Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer
    Pierga, JY
    LaineBidron, C
    Beuzeboc, P
    DeCremoux, P
    Pouillart, P
    Magdelenat, H
    BRITISH JOURNAL OF CANCER, 1997, 76 (04) : 537 - 540
  • [9] Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer
    J-Y Pierga
    C Lainé-Bidron
    P Beuzeboc
    P De Crémoux
    P Pouillart
    H Magdelénat
    British Journal of Cancer, 1997, 76 : 537 - 540
  • [10] Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
    Lampelj, Maja
    Arko, Darja
    Cas-Sikosek, Nina
    Kavalar, Rajko
    Ravnik, Maja
    Jezersek-Novakovic, Barbara
    Dobnik, Sarah
    Dovnik, Nina Fokter
    Takac, Iztok
    RADIOLOGY AND ONCOLOGY, 2015, 49 (04) : 357 - 364